Radical Parkinson's treatment, delivering the drug directly to the brain, has been tested in humans.
Patients in the study either received a drug that was injected through the "port" towards the head or manipulated (placebo).
Both groups showed improved symptoms, that is, it was not clear whether the drug was in favor.
However, the scan showed a visual confirmation of the improvement of affected areas of the brain in those receiving this drug. Other experts, however, say that it's too early to know if this conclusion can lead to improved Parkinson's symptoms.
Researchers believe that a port implant can also be used to administer chemotherapy to people with brain tumors or to test new drugs for Alzheimer's and stroke patients
. Symptoms such as involuntary shaking and stiff, stiff muscles.
For this new study, researchers have given patients an experimental treatment called a neurotrophic factor (GDNF) derived from a line of glial cells, with the hope that it will be able to regenerate dying brain cells and even change the state
. Be introduced directly into the affected areas with precision, through the port in their head.
After the first safety study, 6 people, 35 patients participated in a nine-month "blind" test, where half was randomly assigned to monthly GDNF infusions and the other half of mannequin infusions.
Dr. Alan Won, chief investigator, said that patients had an average of 8 years before in the study, but brain scans of those receiving this drug showed images that could be expected only two years after the diagnosis . with a target, dopamine nerve endings, and it seems to help regenerate damaged cells or have a biological reaction.
"I Feel It Made Me Time"
Tom Fipps, 63, of Bristol, said he noticed improvement during the trial and managed to reduce drug use
After he finished, he slowly increased his drug, but continued to ride a bike, dig in his possession and head for the local department of Parkinson in the UK.
wished, – he said.
"I believe that the test brought me some time and delayed my progress.
"The best part was absolutely a part of a group of people who have the same purpose – not just a team of advisers and nurses, as well as participants
" You can not have expectations – you can only have hope. "
After the first virgins & Forty months on the GDNF or placebo, all participants had the opportunity to receive GDNF for another nineteen months
By the end of the 18 months when all participants received GDNF, both groups showed moderate to significant improvement in symptoms relative to their performance, before they began research.
But the authors claim that re the results should be treated with caution because of the possibility of a placebo effect – when the patient feels better despite medication without an active ingredient.
The researchers hope that further trials may be considered by increasing the dose of GDNF or the duration of treatment.
New Horizons  Dr. Arthur Roach, director of research in the UK who funded the study, said: "Despite the fact that the results are not clearly expressed, the study, nevertheless, was a huge success.
"He advanced our understanding of the potential effects of GDNF on damaged brain cells, showed that the provision of such therapy is possible
Prof. K. Ray Chaudhury of the Institute of Psychiatry, Psychology and Neurology of the Royal College of London, who was not involved in the study, said , that it "disappoints" "that the difference in symptoms was insignificant.
But he said that research is still "of great interest and should point to a new horizon and direction of recovery-based treatment."
The results of the research are published. in the physician l Magazines Brain and Parkinson's Disease Journal.
The study also includes two parts of the BBC Two Documentary Series, The Parkinson's Drug Trial: The Miracle Cure? February 28 and March 7 at 21:00.